Fresh analysis reveals that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop traditional diet and exercise programs.
Findings released in a leading health publication points out that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications need to be informed of the potential of fast rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass in about 18 months.
Weighing Therapies
The analysis, which examined 37 of studies involving over 9,000 of patients, compared the results of these new drugs with conventional dieting.
Researchers note that people who shed pounds through dieting usually see a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Experts propose the mechanism of the injections is key to understanding the heightened weight return.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, considering the likelihood of weight regain, the treatment is often ongoing.
This view is echoed by drug manufacturers, who say that the results "emphasize the persistent character of excess weight," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have stopped the jabs explain a sudden resurgence of appetite.
"It was like a trigger flipping and I was suddenly ravenous," recalled one woman.
This difficulty is compounded if patients have not adopted permanent dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Adoption is greater among females than males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and maintained weight loss hinges on ongoing lifestyle management.